No Data
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
BeiGene Has Entered Into A Settlement Agreement With MSN Pharmaceuticals And MSN Laboratories Private Resolving Patent Litigation Related To MSN's Abbreviated New Drug Application Seeking Approval To Market A Generic Version Of Brukinsa (Zanubrutinib)...
Hillhouse HHLR Q3 hold positions: Chinese concept stocks hold an absolute dominant position, and the total market value of hold positions grew by more than 10%!
①HHLR Advisors, a subsidiary of Hillhouse Capital, saw its total market cap of US stocks holding positions grow by over 10% in the third quarter, with 9 of the top ten heavy positions being Chinese concept stocks; ②HHLR Advisors continued to hold heavy positions in Chinese concept stocks in the third quarter, with the market cap of Chinese concept stocks increasing from 85% in the second quarter to 93% in the third quarter.
What's Going On With US Listed Chinese Stocks Alibaba, JD, Nio, Li XPeng On Wednesday?
BeiGene Shares Are Trading Lower. The Company Reported Q3 Financial Results.
beigene's Q3 single-quarter revenue exceeded 1 billion US dollars. Will the two lawsuits with AbbVie affect future revenue?
①Beigene achieved product revenue of 7.079 billion yuan in the third quarter, with a total quarterly revenue of 7.139 billion yuan, and a revenue of 1.002 billion US dollars under the US GAAP, exceeding 1 billion US dollars in a single quarter for the first time. ②Excluding non-cash items such as share-based payment expenses, depreciation and amortization expenses, Beigene's adjusted operating profit for the third quarter was 65.63 million US dollars.